PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsIntraabdominal infections
MeSH D059413 - intraabdominal infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007239:Infections
$
Success rate
D059413: 
Intraabdominal infections
D001064:Appendicitis
$
Success rate
D010538:Peritonitis
$
Success rate
D053706:Typhlitis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCiprofloxacin Ciprofloxacin  2004-06-09   
Tobramycin Tobramycin  1992-01-30   
PadagisDexamethasone, Tobramycin Tobramycin Dexamethasone  2022-02-11   
Taro PharmaceuticalCiprofloxacin Ciprofloxacin  2004-10-06   
NATCO PharmaCiprofloxacin Ciprofloxacin  2004-06-09   
ViatrisTobramycin Tobi  1997-12-22   
MylanTobramycin Tobramycin  2008-03-11   
Johnson & JohnsonDoripenem Doribax  2008-07-25   
Lupin ResearchTobramycin Tobramycin  2017-03-22   
SandozAmpicillin, Sulbactam Ampicillin Sulbactam  2006-07-25   
Tazobactam, Piperacillin Piperacillin Tazobactam  2010-10-21   
Tigecycline Tigecycline  2015-05-27   
Tobramycin Tobrex  1984-12-13   
Ciprofloxacin Ciloxan  1990-12-31   
Hydrocortisone, Ciprofloxacin Cipro  1998-02-10   
Dexamethasone, Ciprofloxacin Ciprodex 2025-06-04 2003-07-18   
Dexamethasone, Tobramycin Tobradex  1988-08-18   
NovartisDexamethasone, Tobramycin Tobradex  1988-09-28   
Tobramycin Tobrex  1982-01-01   
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
40%
2/5
Phase 2
94%
15/16
Phase 3
71%
34/48
Approved: 15Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
Johnson & Johnson
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use